📰 Clinical Development Program News
Page 10 - Clinical Development Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development Program. Real-time updates on events, politics, business and more.
November 30, 2021
GlaxoSmithKline Inc. today announced that SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) has been approved in Canada for the prevention of shingles (herpes
November 4, 2021
/PRNewswire/ -- Sobi™ will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021....
November 4, 2021
STOCKHOLM, Nov. 4, 2021 /PRNewswire/ -- Sobi will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021. Sobi's commitment
November 4, 2021
/PRNewswire/ -- Sobi™ will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021....
October 26, 2021
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-7, a global phase 3, open-label, randomized trial evaluating the...
October 18, 2021
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that LYBALVI® (olanzapine and samidorphan) is now available by prescription in the United States (U....
October 14, 2021
Tetra Bio-Pharma Inc. , a leader in cannabinoid-derived drug discovery and development today provided an update on the progress and significant achievements of its lead investigational drug,... | October 14, 2021
October 14, 2021
DGAP-News: Tetra Bio-Pharma Inc. / Key word(s): Miscellaneous Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF(TM) 14.10.2021 / 14:39 The issuer is solely responsible for the content of this announcement. Ottawa, October 14, 2021 (CNW) - Tetra Bio-Pharma Inc. (Tetra...
October 14, 2021
DGAP-News: Tetra Bio-Pharma Inc. / Key word(s): Miscellaneous Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF 14.10.2021 / 14:39 The issuer is solely
August 26, 2021
The International Vaccine Institute (IVI) and Bharat Biotech have started a Phase 2/3 clinical trial for a chikungunya vaccine candidate in Costa Rica.